Celgene was originally based in the US but have decided to move over to the UK in order to accommodate their growing numbers on UK-based staff, as well as their expanding global regulatory and drug safety teams.
David Willetts, minister for Universities and Science, opened the new London site and explained that Celgenes UK move would help boost confidence in the UK pharma industry. He stated, “Celgene’s expansion is a vote of confidence in the UK pharmaceutical industry and shows the ability of our life sciences sector to drive growth and create jobs.”
The move comes after a number of Celegene’s recent successes:
- Their multiple myeloma treatment called Revlimind
- Their myeldysplastic syndromes drug called Vidaza
- The acquisition of Abraxis BioScience
- The success of their lead product Abraxane used in the treatment of metastatic breast cancer.